Anthony,
When you have a company that cannot earn any money.
Let me respond to this from the perspective of a biotech investor rather than the day traders that have overrun this thread. I think there is some element of truth to what you say, but I feel you have gone overboard in condemning the stock.
First, I should say that I exited from my own small GERN holding today at 19 7/8. I bought it a while back, when no-one was paying any attention to the stock, which is the right time to buy publicity-prone stocks like GERN and ENMD.
However, I disagree that GERN has dismal prospects. While they are certainly a long way from producing anything like a product, they certainly could strike large deals in the short term with any number of big pharmas, and may well develop a nice business selling their cells in the medium term.
GERN, like ENMD (which I also own a little of, having recently re-entered in the low 20's after selling near the open on "that day"), is certainly not a sure thing, but they both have striking technology that could well emerge into something major. Even though neither have earnings, neither are they no-brainer shorts.
Peter |
